<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02732691</url>
  </required_header>
  <id_info>
    <org_study_id>CP-0003</org_study_id>
    <secondary_id>P02C220_JV06EFS_CIP</secondary_id>
    <secondary_id>CA-0001 EU</secondary_id>
    <secondary_id>CA-0001 Germany</secondary_id>
    <secondary_id>CA-0010</secondary_id>
    <nct_id>NCT02732691</nct_id>
  </id_info>
  <brief_title>THE ALIGN-AS TRIAL: JenaValve Pericardial TAVR Aortic Stenosis Study</brief_title>
  <official_title>THE ALIGN-AS TRIAL: Safety and Effectiveness/Performance of the Transfemoral JenaValve Pericardial TAVR System in the Treatment of Patients With Symptomatic Severe Aortic Stenosis (AS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JenaValve Technology, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>JenaValve Technology, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To collect information about treatment for severe aortic stenosis (AS), which affects the
      aortic valve in the heart. Aortic stenosis is a narrowing of the aortic valve opening, which
      decreases blood flow from the heart and causes symptoms such as chest pain, fainting and
      shortness of breath. The preferred treatment for severe aortic stenosis is aortic valve
      replacement surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine the use of a TAVR (Transcatheter Aortic Valve Replacement), which is
      a minimally invasive procedure designed to replace the aortic valve inside the heart. This
      less invasive surgical approach called TAVR is offered to those patients who are high risk
      for undergoing open heart surgery to replace the aortic valve. In this study, TAVR will be
      performed using the JenaValve Pericardial TAVR System.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">February 2016</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-Cause Mortality at 30 Days</measure>
    <time_frame>30 days</time_frame>
    <description>All-cause mortality rate at 30 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>up to 5 years</time_frame>
    <description>All cause mortality and cardiovascular mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial Infarction</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Peri-procedural and spontaneous myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurological Complications</measure>
    <time_frame>up to 5 years</time_frame>
    <description>TIA and stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding &amp; Vascular Complications</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Major and minor bleeding</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <condition>Heart Valve Diseases</condition>
  <condition>Heart Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Ventricular Outflow Obstruction</condition>
  <arm_group>
    <arm_group_label>Transcatheter Aortic Valve Replacement (TAVR)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve pericardial valve and delivery system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>JenaValve Pericardial TAVR System</intervention_name>
    <description>Transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve Pericardial valve and delivery system.</description>
    <arm_group_label>Transcatheter Aortic Valve Replacement (TAVR)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with severe degenerative native aortic stenosis (AS).

          -  Patient at high risk for open surgical valve replacement

          -  Patient symptomatic according to NYHA functional class II or higher

        Exclusion Criteria:

          -  Congenital uni- or bicuspid aortic valve morphology

          -  Previous prosthetic aortic valve (bioprosthesis or mechanical) implant

          -  Endocarditis or other active infection

          -  Need for urgent or emergent TAVR procedure for any reason

          -  Cardiogenic shock or hemodynamic instability requiring inotropic support or
             ventricular assist device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin B Leon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>New York-Presbyterian Hospital/Columbia University Medical Center, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Torsten Vahl, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York-Presbyterian Hospital/Columbia University Medical Center, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vinod Thourani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University School of Medicine, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hendrik Treede, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Bonn, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>6120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäres Herzzentrum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum der Universität zu Köln</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leiden University Medical Center</name>
      <address>
        <city>Leiden</city>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Hospital</name>
      <address>
        <city>Nieuwegein</city>
        <zip>3435</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erasmus University Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3062</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>3240</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 18, 2016</study_first_submitted>
  <study_first_submitted_qc>April 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2016</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Valvular Heart Disease</keyword>
  <keyword>Critical/Severe Aortic Stenosis</keyword>
  <keyword>High risk symptomatic patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Ventricular Outflow Obstruction</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

